The study describes the successful production and preparation of 45 certified human enterovirus reagents for use as seed viruses and immunizing antigens.
May aid preclinical enterovirus antisera production; leaves open clinical diagnostic or therapeutic translation.
Forty-five human enterovirus reagents of certified purity and quality were prepared for use as seed viruses and as immunizing antigens. One of the reagents was ampouled as "untreated" seed virus, whereas 14 were ampouled as "MgCl(2)-stabilized" reagents. The remaining 30 reagents were ampouled as "untreated" seed viruses and as "MgCl(2)-stabilized" reagents. Thirty of the reagents were propagated on primary African green monkey kidney cells, 3 on primary baboon kidney cells, 3 on primary rhesus monkey kidney cells, and the remaining 9 on human amnion cells. Forty-two of the viral antigens were concentrated for use in the production of high-titered specific antisera in large animals.
No takes yet. Share an insight, caveat, or question.
Kalter et al. (1968) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: